// App-Quantinova.ai

AB0226 (2022) : CLINICAL SIGNIFICANCE OF SOLUBLE ST2 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).

Researchers

Presenter

  • Y. Gorbunova

Principal Investigators

  • T. Popkova

  • I. Kirillova

  • L. Kondrateva

  • M. Diatroptov

  • A. Lila

  • E. Nasonov

Medical Centers

  • VA Nasonova Research Institute of Rheumatology, of Systemic Rheumatic Diseases, Moscow, Russian Federation

  • V.A.Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation

  • V.A. Nasonova Research Institute of Rheumatology, Educational-Methodical Department, Moscow, Russian Federation

Locations

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • anti-CCP antibodies

  • Interleukin 6

Drug/Treatment

  • Hydroxychloroquine

  • Glucocorticoid

  • Sulfasalazine

  • Methotrexate

  • leflunomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved